Pancreatic neuroendocrine tumors: Does chemotherapy work?

Journal of the Pancreas

Volumn 15, Issue 2, 2014, Pages 132-134

  Tejani, Mohamedtaki Abdulaziz ^a   Saif, Muhammad Wasif ^b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Capecitabine; Neuroendocrine tumors; Temozolomide

Indexed keywords

CAPECITABINE; DOXORUBICIN; EVEROLIMUS; FLUOROPYRIMIDINE; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE;

ALGORITHM; CANCER GROWTH; CONFERENCE PAPER; DIARRHEA; DNA POLYMORPHISM; GASTROINTESTINAL TRACT; HUMAN; LYMPHOCYTOPENIA; METASTASIS RESECTION; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84897875613     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: 10.6092/1590-8577%2F2301     Document Type: Conference Paper

References (9)

1. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005; 12: 1083.
2. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebcontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656.
3. Raymond E, Dahan L, Raoul JL, et al. Sunitinib maleate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501.
4. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514.
5. Fine RL, Gulati AP, Tsushima D, et al. Prospective Phase II study of capecitabine and temozolamide for progressive, moderately and well-differentiated metastatic neuroendocrine tumors. J Clin Oncol 2014; 32: abstract 179
6. Spada F, Fumagalli C, Antonuzzo L, et al. Capecitabine and temozolamide in patients with advanced neuroendocrine neoplasms: An Italian multicenter retrospective analysis. J Clin Oncol 2014; 32: abstract 281.
7. Peixoto RD, Noonan K, Kennecke HF, et al. Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (pNETs) and nonpNETs. J Clin Oncol 2014; 32: abstract 343.
8. Saif MW, Kaley K, Brennan M, Garcon MC, Rodriguez G, Rodriguez T. A retrospective study of capecitabine/temozolamide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors after failing previous therapy. JOP. J Pancreas (Online) 2013; 14:498-501.
9. U.S. National Institutes of Health. Temozolomide with or without capecitabine in treating patients with advanced pancreatic neuroendocrine tumors. ClinicalTrials.gov (NCT 01824875). Accessed January 28, 2014 http://www.clinicaltrials.gov/ct2/show/NCT01824875?term=01824875&rank=1